Clinical Analysis of Primary Central Nervous System Lymphoma: of 21 Cases Report

Jing Wang,Ping Wang,Qingsong Pang

DOI: https://doi.org/10.3969/j.issn.1000-8179.2007.18.008

2007-01-01

Chinese Journal of Clinical Oncology

Abstract:Objective: Primary central nervous system lymphoma (PCNSL) is a type of lymphoma which originates in the central nervous system and does not spread to other systems. The incidence of PCNSL is increasing, and its prognosis is poor. This study aims to investigate the diagnosis of PCNSL and to explore the most effective treatment for PCNSL in immunocompetent patients. Methods: Twenty-one cases (12 men and 9 women) with pathologically confirmed PCNSL were treated in our hospital from June 1993 to June 2006. The clinical characteristics, the differential diagnosis and the treatments were reviewed retrospectively. SPSS 11.5 statistical analysis software was used to compare the two methods of treatment: chemotherapy after radiotherapy and radiotherapy after chemotherapy. The survival curves were calculated according to the Kaplan-Meier method and compared the Log-rank test. Results: The age of the patients ranged from 46 to 55 years old (median age=50). Multiple lesions were reported in 6 cases and single lesions in 15 cases. Computed tomography (CT) and magnetic resonance image (MRI) showed unique or multiple periventricular, uniformly enhancing lesions with mass effect, clear margins and moderate perifocal edema. All cases were B-cell lymphoma. No positive case of cerebrospinal fluid (CSF) was found upon cellular examination. Three cases received stereotactic brain biopsy while others were given surgical treatment. Two cases received radiotherapy only after surgery; two cases received chemotherapy only after stereotactic brain biopsy while the remaining 17 cases received both radiotherapy and chemotherapy after stereotactic brain biopsy or resection. We divided the 17 patients into two groups: Group 1 and 2. Group 1 was given chemotherapy after radiotherapy, while Group 2 was given radiotherapy after chemotherapy. Kaplan-Meier analysis showed that the median survival time (MST) was 22.6 months and the 2-year survival rate was 44.5% across the whole group. Log-Rank test revealed that the survival time shows no statistical difference between Group 1 and Group 2 (P=0.054 7). The MST of Group 1 and Group 2 were 36 months and 19 months and the 2-year survival rates were 66.7% and 35.7%, respectively. Conclusion: PCNSL often occurs in middle-aged patients, with intracranial hypertension as the main clinical manifestation. B-cell lymphoma is the main pathological subtype. It is difficult to distinguish PCNSL from other central nervous system tumors only according to their clinical manifestations and radiological findings. Accurate diagnosis is determined by pathological examination. Resection provides no therapeutic benefit but should be reserved for the rare patients with neurologic deterioration due to herniation. PCNSL suspected in neurologic imaging must be confirmed via stereotactic biopsy. Characteristic imaging features should corroborate the diagnosis and surgery should be avoided. The combination of radiotherapy and chemotherapy was feasible and efficient. It improves tumor response rates and survival rates compared with whole brain radiotherapy (WBRT) alone or chemotherapy alone. High-dose MTX-based chemotherapy plus WBRT (30-4QGy) showed significant efficacy for PCNSL. The sequence of radiotherapy and chemotherapy did not significantly influence the overall survival, but the MST and the 2-year survival rate are significantly different between the two groups. Radiotherapy followed by chemotherapy is superior to chemotherapy followed by radiotherapy.